Desarrollo de una aplicación móvil para el diagnóstico y tratamiento de la infección por H. pylori para profesionales de la salud

dc.contributor.advisorRodríguez Gutiérrez, Andrés Fernandospa
dc.contributor.advisorHernández Ruiz, Jaime Arturospa
dc.contributor.authorEspitia Olarte, Jonathan Danyspa
dc.date.accessioned2021-11-03T19:54:04Z
dc.date.available2021-11-03T19:54:04Z
dc.date.issued2021-10-02
dc.descriptionilustraciones, gráficas, tablasspa
dc.description.abstractLa infección por Helicobacter pylori (HP) ha sido una de las más estudiadas en las últimas décadas, su prevalencia es de alrededor del 60% de la población adulta y se relaciona con diversos trastornos de origen gastrointestinal tales como gastritis crónica, úlcera péptica, linfoma de tipo MALT (linfoma de tejido linfoide asociado a mucosas) y en el 1 al 3% se encuentra asociado a cáncer gástrico, entre otros. Los principales síntomas se presentan en un 20% de los pacientes, y en un gran porcentaje pueden ser asintomáticos 80%. El diagnóstico se basa en pruebas invasivas como la endoscopia digestiva alta y no invasivas como antígenos fecales y test respiratorio de aliento con urea marcada con carbono C13 y C14. La terapia triple estándar incluye antibióticos como la Claritromicina y Metronidazol, a los cuales el HP tiene altas tasas de resistencia en Latinoamérica. En la actualidad se utilizan terapias cuádruples adicionando el subsalicitalo de bismuto, con una efectividad hasta del 90% cuando esta se administra por 14 días. Erradicar H pylori trae múltiples beneficios entre ellos la prevención del cáncer gástrico en etapas tempranas entre otros. El diagnóstico y tratamiento oportuno y adecuado puede prevenir las complicaciones derivadas de la infección; sin embargo, la complejidad en el tratamiento por los múltiples esquemas hace necesario estrategias didácticas que faciliten el aprendizaje y aplicación en el diagnóstico del H. pylori. Objetivo: El propósito de este trabajo consiste en realizar una revisión compresiva del diagnóstico y tratamiento del H. pylori, a partir del desarrollo un aplicativo móvil de fácil acceso y de rápida consulta dirigido a los trabajadores de la salud, y así brindar una herramienta útil para el diagnóstico y el tratamiento de la infección por el h. pylori, así como mejorar indicadores de pertinencia, oportunidad e idoneidad en la búsqueda y tratamiento de la infección por H. pylori. Dentro de los beneficios al erradicar el H. pylori se reflejan en la reducción de úlcera péptica, disminución del riesgo de progresión de gastritis crónica cuando esta es superficial y menor progresión de lesiones precursoras de neoplasias gástricas en estadios tempranos, entre otras. Metodología: Este trabajo se desarrolla en 2 partes, en la primera, se realizó una revisión narrativa extensa que incluyó una búsqueda de la literatura en diversas fuentes de información médica como guías de práctica clínica, revisiones narrativas y estudios primarios en bases de datos como Embase, Lilacs, Pubmed y literatura gris y se resuelven 6 preguntas muy frecuentes sobre el diagnóstico y tratamiento en el paciente que asiste por infección por H. pylori. En la segunda parte, se desarrolló un aplicativo móvil en salud en la plataforma Android con la plataforma MIT app inventor, para dispositivos móviles y por medio de algoritmos enfocados en el diagnóstico y tratamiento de la infección por H. pylori, y se evaluó su aplicabilidad y desempeño en escenarios clínicos reales en servicios de consulta externa y medicina interna. Resultados: Se logró una revisión narrativa completa de los temas de interés y se desarrolló y publicó en la Play Store de Android, la aplicación móvil de nombre “PyloriApp”, en la que se presentan de forma sencilla y amigable las indicaciones de tamización del H. pylori y otras indicaciones de endoscopia digestiva alta, los métodos de diagnóstico que permiten dar continuidad en el abordaje del paciente con infección por H. pylori, generando así mejoría en la toma de decisiones clínicas de manera rápida e informada, mayor seguridad y pertinencia en el diagnóstico y tratamiento por la infección por H. pylori. (Texto tomado de la fuente).spa
dc.description.abstractHelicobacter pylori (HP) infection has been one of the most studied in recent decades, its prevalence is around 60% of the adult population and is related to various gastrointestinal disorders such as chronic gastritis, peptic ulcer, lymphoma MALT type (mucosa-associated lymphoid tissue lymphoma) and in 1 to 3% it is associated with gastric cancer, among others. The main symptoms occur in 20% of patients, and 80% may be asymptomatic in a large percentage. Diagnosis is based on invasive tests such as upper gastrointestinal endoscopy and non-invasive tests such as fecal antigens and C13 and C14 carbon-labeled urea respiratory breath test. Standard triple therapy includes antibiotics such as Clarithromycin and Metronidazole, to which HP has high rates of resistance in Latin America. At present, quadruple therapies are used by adding bismuth subsalicylic acid, with an effectiveness of up to 90% when it is administered for 14 days. Eradicating H pylori brings multiple benefits, including the prevention of gastric cancer in early stages, among others. Timely and adequate diagnosis and treatment can prevent complications derived from infection; however, the complexity in the treatment due to the multiple schemes makes it necessary to didactic strategies that facilitate learning and application in the diagnosis of H. pylori.. Objective: The purpose of this work is to carry out a comprehensive review of the diagnosis and treatment of H. pylori, based on the development of a mobile application with easy access and quick consultation aimed at health workers, and thus provide a useful tool for the diagnosis and treatment of infection by h. pylori, as well as improving indicators of relevance, opportunity and suitability in the search for and treatment of H. pylori infection. Among the benefits of eradicating H. pylori are reflected in the reduction of peptic ulcer, decreased risk of progression of chronic gastritis when it is superficial and less progression of precursor lesions of gastric neoplasms in early stages, among others. Methodology: This work is developed in 2 parts, in the first, an extensive narrative review was carried out that included a search of the literature in various sources of medical information such as clinical practice guidelines, narrative reviews and primary studies in databases such as Embase, Lilacs , Pubmed and gray literature and 6 very frequently asked questions about the diagnosis and treatment in the patient attending for H. pylori infection are resolved. In the second part, a mobile health application was developed on the Android platform with the MIT app inventor platform, for mobile devices and through algorithms focused on the diagnosis and treatment of H. pylori infection, and its applicability was evaluated. and performance in real clinical scenarios in outpatient and internal medicine services. Results: A complete narrative review of the topics of interest was achieved and the mobile application called “PyloriApp” was developed and published in the Android Play Store, in which the indications for H screening are presented in a simple and friendly way. pylori and other indications for upper gastrointestinal endoscopy, the diagnostic methods that allow continuity in the approach to the patient with H. pylori infection, thus generating improvement in clinical decision-making in a fast and informed way, greater safety and relevance in the diagnosis and treatment of H. pylori infection.eng
dc.description.degreelevelEspecialidades Médicasspa
dc.description.degreenameEspecialista en Medicina Internaspa
dc.format.extent41 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/80648
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.departmentDepartamento de Medicina Internaspa
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Medicina - Especialidad en Medicina Internaspa
dc.relation.referencesHooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420–9.spa
dc.relation.referencesOtero W. Cáncer gástrico y Helicobacter pylori ¿Sí o no? http://www.actamedicacolombiana.com/anexo/articulos/03-2000-02.htm. 2000. p. 1.spa
dc.relation.referencesCover TL, Blaser MJ. Helicobacter pylori in Health and Disease. Gastroenterology [Internet]. 2009;136(6):1863–73. Available from: doi:10.1053/j.gastro.2009.01.073.spa
dc.relation.referencesSugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–1367.spa
dc.relation.referencesGisbert JP, Molina-Infate J, Amador J, Bermejo F, Bujanda L. IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterol Hepatol. 1048:1–25spa
dc.relation.referencesFallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology [Internet]. 2016;151(1):51-69.e14. Available from: http://dx.doi.org/10.1053/j.gastro.2016.04.006spa
dc.relation.referencesChey D W, Leontiadis GI, Howden CW, Steven F M. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112:212–238.spa
dc.relation.referencesO´Connor A, O´Morain CA, Ford AC. Population screening and treatment of Helicobacter pylori infection. Nat Rev. 14:231–40.spa
dc.relation.referencesInternational Agency for Research on Cancer, World Health Organization. Helicobacter pylori eradication as a strategy for preventing gastric cancer. IARC Work Gr Reports, No8 [Internet]. 2014;8:4. Available from: http://www.iarc.fr/en/publications/pdfs- online/wrk/wrk8/index.phpspa
dc.relation.referencesAtherton JC, Blaser MJ. Infecciones por Helicobacter pylori. In: Harrison Principios de Medicina Interna - 20°. 2018. p. 1162–6.spa
dc.relation.referencesMezmale L, Coelho LG, Bordin D, Leja M. Review: Epidemiology of Helicobacter pylori. Helicobacter WILEY. 2020;25:1–5.spa
dc.relation.referencesStefano K, Marco M, Federica G, Laura B, Barbara B. Helicobacter pylori, transmission routes and recurrence of infection: state of the art. Acta Biomed. 2018;89:72–76.spa
dc.relation.referencesKotilea K, Bontems P, Touati E. Epidemiology, Diagnosis and Risk Factors of Helicobacter pylori Infection. Adv Exp Med Biol - Adv Microbiol Infect Dis Public Heal Springer Nat. 2019;1–17.spa
dc.relation.referencesLash RH, Genta RM. Routine Anti-Helicobacter Immunohistochemical Staining is Significantly Superior to Reflex Staining Protocols for the Detection of Helicobacter in Gastric Biopsy Specimens. Helicobacter WILEY. 2016;21:581–5.spa
dc.relation.referencesMichael F D, Robert G, John Y, Pelayo C. Classification and grading of gastritis. The updated Sydney System. Am J Surg Pathol. 1994;20.spa
dc.relation.referencesMcNulty CA, Wise R. Rapid diagnosis of Campylobacter- associated gastritis. Lancet. 1985;1:1443–4.spa
dc.relation.referencesPatrick B, Jeanne-Marie D, Luigi C, Antal D. Twelve year observation of primary and secondary antibiotic-resistant Helicobacter pylori strains in children. Pediatr Infect Dis J. 20:1033–8.spa
dc.relation.referencesMiendje Deyi VY, Bontems P, Vanderpas J, De Koster E, Ntounda R. Multicenter Survey of Routine Determinations of Resistance of Helicobacter pylori to Antimicrobials over the Last 20 Years (1990 to 2009) in Belgium. J Clin Microbiol. :2200–2209.spa
dc.relation.referencesGraham DY, Klein PD, Evans DJ, Alpert LC. Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet. 1:1174–7.spa
dc.relation.referencesUotani T, Graham DY. Diagnosis of Helicobacter pylori using the rapid urease test. Ann Transl Med. 2015;3:1–7.spa
dc.relation.referencesLeal YA, Flores LL, Fuentes-Pananá EM, Cedillo-Rivera R, Torres J. 13C-Urea Breath Test for the Diagnosis of Helicobacter pylori Infection in Children: A Systematic Review and Meta-Analysis. Helicobacter. 2011;16:327–337.spa
dc.relation.referencesMauro M, Radovic V, Wolfe M, Kamath M. 13C urea breath test for Helicobacter pylori: Evaluation of 10-minute breath collection. Can J Gastroenterol. 2006;20(12):1–4.spa
dc.relation.referencesBurucoa C, Delchier J-C, Courillon-Mallet A, De Korwin J-D. Comparative Evaluation of 29 Commercial Helicobacter pylori Serological Kits. Helicobacter WILEY. 2013;18:169–79spa
dc.relation.referencesWestblom TU, Madan E, Gudipati S, Midkiff BR. Diagnosis of Helicobacter pylori Infection in Adult and Pediatric Patients by Using Pyloriset, a Rapid Latex Agglutination Test. J Clin Microbiol. :96–8.spa
dc.relation.referencesMakristathis A, Pasching E, Schutze K, Wimmer M. Detection of Helicobacter pylori in Stool Specimens by PCR and Antigen Enzyme Immunoassay. J Clin Microbiol. :2772–2774.spa
dc.relation.referencesGuarner J, Kalach N, Elitsur Y, Koletz K. Helicobacter pylori diagnostic tests in children: review of the literature from 1999 to 2009. Eur J Pediatr. 2010;169:15–25.spa
dc.relation.referencesEarly DS, Ben-Menachem T, Decker GA, Evans JA. Appropriate use of GI endoscopy. Gastrointest Endosc. 2012;75:1127–31.spa
dc.relation.referencesOtero W, Gómez M, Trespalacios AA. Helicobacter pylori: después de todo. Asoc Colomb Gastroenterol. 2007;43–56.spa
dc.relation.referencesParsonnet J. Helicobacter pylori: the size of the problem. Epidemiol H pylori Infect. 1998;43:S6–S9.spa
dc.relation.referencesMuhsen K, Cohen D. Helicobacter pylori Infection and Iron Stores: A Systematic Review and Meta-analysis. J Compil Helicobacter. 2008;323–340.spa
dc.relation.referencesStasi R, Sarpatwari A, B. Segal J, Osborn J, Evangelista ML. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. www.bloodjournal.org. 113 No. 6:1231–9.spa
dc.relation.referencesLahner E, Persechino S, Annibale B. Micronutrients (Other than iron) and Helicobacter pylori Infection: A Systematic Review. Helicobacter. 2012;17:1–15.spa
dc.relation.referencesJemal A, Siegel R, Ward E. Cancer Statistics, 2008. CA Cancer J Clin. 2008;58:71–96spa
dc.relation.referencesLeung WK, Wu M, Kakugawa Y, Kim JJ. Screening for gastric cancer in Asia: current evidence and practice. http://oncology.thelancet.com. 9:279–87.spa
dc.relation.referencesGoodman K, Cockburn M. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49:347–353.spa
dc.relation.referencesMalfertheiner P, Megraud F, O´Morain CA, Gisbert JP, Kuipers EJ. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. BMJ. 2017;66:6–30.spa
dc.relation.referencesGisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter WILEY. 2017;1:1–13.spa
dc.relation.referencesGraham DY, Pina Dore M. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;1–35.spa
dc.relation.referencesNeumeister P, Troppan K, Raderer M. Management of gastric mucosa-associated lymphoid tissue lymphoma. Epub. 2015;33:11–8.spa
dc.relation.referencesGraham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract. 5:321–31.spa
dc.relation.referencesYonezawa H, Osaki T, Kamiya S. Biofilm Formation by Helicobacter pylori and Its Involvement for Antibiotic Resistance. Biomed Res Int. 2015;1–10.spa
dc.relation.referencesGisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, et al. IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterol Hepatol [Internet]. 2016;39(10):697–721. Available from: http://dx.doi.org/10.1016/j.gastrohep.2016.05.003spa
dc.relation.referencesVILLORIA A, GARCIA P, CALVET X, Gisbert JP, VERGARA M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28:868–877.spa
dc.relation.referencesFuruta T, Graham DY. Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection. Gastroenterol Clin N Am. 2010;39:465–480.spa
dc.relation.referencesFuruta T, Sugimoto M, Yamade M, Uotani T, Sahara S. Effect of Dosing Schemes of Amoxicillin on Eradication Rates of Helicobacter pylori With Amoxicillin‐Based Triple Therapy. Am Coll Clin Pharmacol. 2013;54:258–266spa
dc.relation.referencesSHIOTANI A, LU H, Dore MP, Graham DY. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve Clin J Med. 2017;1–19.spa
dc.relation.referencesDucournau A, Bénéjat L, Sifré E, Bessède E, Lehours P. Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods. Clin Microbiol Infect. 2016;1–15.spa
dc.relation.referencesArevalo JA, Miron Canelo J. Aplicaciones móviles en salud: potencial, normativa de seguridad y regulación. Rev Cuba Inf en Ciencias la Salud [Internet]. 2017;28:1–13. Available from: http://scielo.sld.cu/pdf/ics/v28n3/rci05317.pdfspa
dc.relation.referencesmHealth New horizons for health through mobile technologies. WHO Libr Cat Data. 2011;3:1–112.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseReconocimiento 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/spa
dc.subject.ddc610 - Medicina y salud::616 - Enfermedadesspa
dc.subject.decsMedical Informatics Applicationseng
dc.subject.decsAplicaciones de la Informática Médicaspa
dc.subject.decsHelicobacter pylorieng
dc.subject.decsHelicobacter pylorispa
dc.subject.decsPersonal de Saludspa
dc.subject.decsHealth Personneleng
dc.subject.proposaleSaludspa
dc.subject.proposalTelesaludspa
dc.subject.proposalAndroidspa
dc.subject.proposalInfecciónspa
dc.subject.proposalHelicobacter pyloriother
dc.subject.proposalDiagnósticospa
dc.subject.proposalTratamientospa
dc.subject.proposalAplicaciónspa
dc.subject.proposalMóvilspa
dc.subject.proposalDispositivosspa
dc.subject.proposalAlgoritmosspa
dc.subject.proposalInfectioneng
dc.subject.proposalDiagnosiseng
dc.subject.proposalTreatmenteng
dc.subject.proposalMobileeng
dc.subject.proposalApplicationeng
dc.subject.proposalDeviceseng
dc.subject.proposalAlgorithmseng
dc.titleDesarrollo de una aplicación móvil para el diagnóstico y tratamiento de la infección por H. pylori para profesionales de la saludspa
dc.title.translatedDevelopment of a mobile application for the diagnosis and treatment of H. pylori infection for health professionalseng
dc.typeTrabajo de grado - Especialidad Médicaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentPúblico generalspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
1053330038.2021.pdf
Tamaño:
922.48 KB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Especialidad en Medicina Interna

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
3.98 KB
Formato:
Item-specific license agreed upon to submission
Descripción: